These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26203642)

  • 1. Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations.
    Katz SJ; Kurian AW; Morrow M
    JAMA; 2015 Sep; 314(10):997-8. PubMed ID: 26203642
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic mastectomy and genetic testing: an update.
    Houshmand SL; Campbell CT; Briggs SE; McFadden AW; Al-Tweigeri T
    Oncol Nurs Forum; 2000; 27(10):1537-47; quiz 1548-9. PubMed ID: 11103373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic counseling and management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations.
    Silva E; Lynch H
    Breast J; 2006; 12(3):280-1; author reply 282-4. PubMed ID: 16684334
    [No Abstract]   [Full Text] [Related]  

  • 5. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing.
    Tercyak KP; Peshkin BN; Brogan BM; DeMarco T; Pennanen MF; Willey SC; Magnant CM; Rogers S; Isaacs C; Schwartz MD
    J Clin Oncol; 2007 Jan; 25(3):285-91. PubMed ID: 17159191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contralateral risk-reducing mastectomy in young women.
    Merck B
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():29-32. PubMed ID: 20711671
    [No Abstract]   [Full Text] [Related]  

  • 7. Lessons learned from genetic testing.
    Esserman L; Kaklamani V
    JAMA; 2010 Sep; 304(9):1011-2. PubMed ID: 20810382
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes of breast cancer patients with and without BRCA1/2 mutations.
    Fatouros M; Ziogas D; Roukos DH
    Int J Cancer; 2008 Apr; 122(8):1918-9. PubMed ID: 18074347
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of BRCA mutation testing in determining breast cancer therapy.
    Trainer AH; Lewis CR; Tucker K; Meiser B; Friedlander M; Ward RL
    Nat Rev Clin Oncol; 2010 Dec; 7(12):708-17. PubMed ID: 21060331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailoring breast cancer therapy to genetic status.
    Seynaeve C; Brekelmans CT
    Lancet; 2005 May 14-20; 365(9472):1672-3. PubMed ID: 15894086
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Halbert CH; DeMarco T; Lawrence W; Main D; Finch C; Magnant C; Pennanen M; Tsangaris T; Willey S; Isaacs C
    J Clin Oncol; 2004 May; 22(10):1823-9. PubMed ID: 15067026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
    Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted tailored management of the breast cancer patient at risk for harboring a germline mutation-current trends affecting the selection of patients considering surgical prophylaxis for breast cancer.
    Silva E
    Breast J; 2009; 15 Suppl 1():S76-80. PubMed ID: 19775334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAMA patient page. BRCA genes and breast cancer.
    Pluta RM; Golub RM
    JAMA; 2011 Jun; 305(21):2244. PubMed ID: 21632489
    [No Abstract]   [Full Text] [Related]  

  • 15. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
    Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
    JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy.
    McQuirter M; Castiglia LL; Loiselle CG; Wong N
    Oncol Nurs Forum; 2010 May; 37(3):313-20. PubMed ID: 20439215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Armstrong K; Weber BL
    Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
    [No Abstract]   [Full Text] [Related]  

  • 20. Radiotherapy for breast cancer in BRCA1/BRCA2 carriers: clinical issues and management dilemmas.
    Pierce L
    Semin Radiat Oncol; 2002 Oct; 12(4):352-61. PubMed ID: 12382193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.